Efficacy/Safety of Lansoprazole in Patients With Frequent Heartburn
Launched by NOVARTIS · Oct 18, 2006
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Experiencing heartburn at least 2 days per week over the past month.
- • 2. Having heartburn that responds to heartburn medication.
- • 3. Be willing to discontinue the use of heartburn treatment for 7 days prior to inclusion in the study.
- Exclusion Criteria:
- • 1. Having history of erosive esophagitis or gastroesophageal reflux disease diagnosed by a physician and confirmed by testing (endoscopy).
- • 2. Be unwilling to take only the study medication, and antacid provided as a rescue medication for relief of acute heartburn during the study.
- • Other protocol-defined inclusion or exclusion criteria may apply
About Novartis
Novartis is a global healthcare company based in Switzerland, dedicated to reimagining medicine to improve and extend people's lives. With a strong focus on innovative pharmaceuticals, Novartis engages in the research, development, and commercialization of a wide range of therapies across various therapeutic areas, including oncology, cardiology, immunology, and neuroscience. The company is committed to advancing clinical research through rigorous trials that prioritize patient safety and efficacy, aiming to deliver groundbreaking treatments and solutions that address unmet medical needs worldwide. Novartis's commitment to innovation and collaboration positions it at the forefront of the biopharmaceutical industry, driving advancements that enhance patient care and health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Miami, Florida, United States
Portland, Oregon, United States
Nashville, Tennessee, United States
Lakewood, Washington, United States
Evansville, Indiana, United States
St. Louis, Missouri, United States
San Angelo, Texas, United States
Salisbury, North Carolina, United States
Fort Worth, Texas, United States
Hialeah, Florida, United States
Sierra Vista, Arizona, United States
Reisterstown, Maryland, United States
Hoover, Alabama, United States
Huntsville, Alabama, United States
Los Angeles, California, United States
Roseville, California, United States
Jupiter, Florida, United States
Atlanta, Georgia, United States
Omaha, Nebraska, United States
Rio Rancho, New Mexico, United States
Port Chester, New York, United States
Columbus, Ohio, United States
Carnegie, Pennsylvania, United States
Johnson City, Tennessee, United States
Dallas, Texas, United States
Richmond, Virginia, United States
Richmond, Virginia, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials